Confirm with Kaiser member services
If those factors are all optimized and the stall persists for 4 or more weeks, a dose increase may be appropriate
Safety and Tolerability: Clinical Studies for Approval: Long-term trials (at least one year) are required for chronic treatments like obesity therapies to demonstrate sustained efficacy and to monitor for adverse effects
J Clin Invest 2015, 125: 47144728
According to an agency press release issued Tuesday, the enforcement action centers on telehealth firms that marketed compounded versions of semaglutide, tirzepatide and liraglutide products, in ways that suggested equivalence with FDA-approved therapies such as Wegovy, Ozempic, Mounjaro and Zepbound
One important change is that they state, GLP-1 RA therapy may be continued preoperatively in patients without elevated risk of delayed gastric emptying. The risk factors they state include: escalation phase of dosing, higher dose, weekly dosing (as opposed to daily dosing), gastrointestinal symptoms (nausea, vomiting, abdominal pain, dyspepsia, constipation), and medical conditions that may cause delayed gastric emptying
